Location of Repository

Unusual DNA binding modes for metal anticancer complexes

By Ana M. Pizarro and P. J. Sadler

Abstract

DNA is believed to be the primary target for many metal-based drugs. For example, platinum-based anticancer drugs can form specific lesions on DNA that induce apoptosis. New platinum drugs can be designed that have novel modes of interaction with DNA, such as the trinuclear platinum complex BBR3464. Also it is possible to design inert platinum(IV) pro-drugs which are non-toxic in the dark, but lethal when irradiated with certain wavelengths of light. This gives rise to novel DNA lesions which are not as readily repaired as those induced by cisplatin, and provides the basis for a new type of photoactivated chemotherapy. Finally, newly emerging ruthenium(II) organometallic complexes not only bind to DNA coordinatively, but also by H-bonding and hydrophobic interactions triggered by the introduction of extended arene rings into their versatile structures. Intriguingly osmium (the heavier congener of ruthenium) reacts differently with DNA but can also give rise to highly cytotoxic organometallic complexes

Topics: RC0254
Publisher: Elsevier Masson
Year: 2009
OAI identifier: oai:wrap.warwick.ac.uk:3369

Suggested articles

Preview

Citations

  1. (2006). 10108-10114.Unusual DNA binding modes for metal anticancer complexes doi
  2. (2000). A complete kinetic study of GG versus AG plantination suggests that the doubly aquated derivatives of cisplatin are the actual DNA binding species, doi
  3. (1999). A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts,
  4. (1999). A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system,
  5. (2004). A Phase I and Pharmacological Study with Imidazolium-transDMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent, Clin. Cancer Res. doi
  6. (1981). A platinum-195 and nitrogen-15 NMR study of the anticancer drug cis-diamminedichloroplatinum(II) and its hydrolysis and oligomerization products, doi
  7. (2001). A Platinum(IV) Complex Oxidizes Guanine to 8-Oxo-Guanine in doi
  8. (2007). A potent cytotoxic photoactivated platinum complex, doi
  9. (2006). A Third Mode of DNA Binding: Phosphate Clamps by a Polynuclear Platinum Complex, doi
  10. (2003). Activation of Trans Geometry in Bifunctional Mononuclear Platinum Complexes by a Piperidine Ligand: Mechanistic Studies on Antitumor Action, doi
  11. (1985). Activity of JM9 in advanced ovarian cancer: a phase I-II trial,
  12. (1985). Adducts of the antitumor drug cisdiamminedichloroplatinum(II) with DNA: formation, identification, and quantitation, doi
  13. (1991). An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV)(tetraplatin) in the L1210 cell line,
  14. (2003). Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers, doi
  15. (1999). Anticancer activity of cisplatin and related complexes, 1 doi
  16. (1992). Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats, doi
  17. (1980). Antitumor activity of platinum(II) complexes of l,2-diammino-cyclohexane isomers, doi
  18. (1994). Aquation of the anticancer complex trans-[RuCl4(Him)2]- (Him = doi
  19. (1999). Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins,
  20. (2000). BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin,
  21. (1985). Binding of the antitumor drug cisdiamminedichloroplatinum(II) (cisplatin) to DNA, doi
  22. (1977). Biological activity of ruthenium purine complexes,
  23. (1989). biological and antitumor properties of ruthenium(II) complexes with dimethyl sulfoxide, doi
  24. (1988). Bis(platinum) complexes containing two platinum cis-diammine units. Synthesis and initial DNA-binding studies, doi
  25. (1999). Cellular pharmacology of polynuclear platinum anti-cancer agents, doi
  26. (2008). Cellular Uptake,
  27. (1983). Characterization of the adducts produced in DNA by cisdiamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II), doi
  28. (2007). Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands, doi
  29. (2007). Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity, doi
  30. (1987). cisDiamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cisdiamminedichloroplatinum(II),
  31. (1997). Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP, doi
  32. (1999). Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug, Verlag Helvetica Chimica Acta, doi
  33. (2000). Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex,
  34. (1986). Clinical development of iproplatin doi
  35. (1989). Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group, doi
  36. (2006). Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts, doi
  37. (1987). Comparative antitumor activity of ruthenium derivatives with 5'-deoxy-5-fluorouridine in chemically induced colorectal tumors in SD rats, doi
  38. (1988). Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer, doi
  39. (2005). Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide, doi
  40. (2005). Conformation, protein recognition and repair of DNA interstrand and intrastrand cross-links of antitumor trans-[PtCl2(NH3)(thiazole)], doi
  41. (1996). Coordination chemistry of metallodrugs: insights into biological speciation from NMR spectroscopy, doi
  42. (1995). Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin, doi
  43. (2000). Current status of the development of trans-platinum antitumor drugs, doi
  44. (1989). Cytostatic trans-platinum(II) complexes, doi
  45. (1990). Detection of DNA strand breaks in Escherichia coli treated with platinum(IV) antitumor compounds, doi
  46. (1999). Development and application of a simple assay to quantify cellular adducts of platinum complexes with DNA,
  47. (2006). Development of Organometallic Ruthenium-Arene Anticancer Drugs That Resist Hydrolysis, doi
  48. (2007). Direct Cellular Responses to Platinum-Induced doi
  49. (2006). Diversity in guanine-selective DNA binding modes for an organometallic ruthenium arene complex, doi
  50. (1998). DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)], doi
  51. (2002). DNA Interstrand Cross-links of the Novel Antitumor Trinuclear Platinum Complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair, doi
  52. (1999). DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent, doi
  53. (2003). DNA-protein cross-linking by trans-[PtCl2(E-iminoether)2]. A concept for activation of the trans geometry in platinum antitumor complexes, doi
  54. (1983). Does the antitumoral activity of platinum(IV) derivatives result from their in vivo reduction?,
  55. (1995). Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II),
  56. (1989). Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats,
  57. (2000). Enhanced binding of the TATAbinding protein to TATA boxes containing flanking cisplatin 1,2-cross-links, doi
  58. (1995). Formation of DNA Adducts by the Anticancer Drug Carboplatin: Different Nucleotide Sequence Preferences in Vitro and in Cells, doi
  59. (2003). Formation of platinated GG cross-links on DNA by photoactivation of a platinum(IV) azide complex, doi
  60. (2006). From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A), doi
  61. (1987). Glutathione-mediated activation of anticancer platinum(IV) complexes, doi
  62. (1991). Guanine-O6 methylation reduces the reactivity of d(GpG) towards platinum complexes, doi
  63. (2005). Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells, doi
  64. (2005). High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro, doi
  65. (2003). Highly Selective Binding of Organometallic Ruthenium Ethylenediamine Complexes to Nucleic Acids: Novel Recognition Mechanisms, doi
  66. (1994). HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancerUnusual DNA binding modes for metal anticancer complexes drug cisplatin by human excision nuclease, doi
  67. (1992). Hydrolysis products of cisplatin: pKa determinations via [1H, 15N] doi
  68. (1988). Identification of cis-dichloro-bis-isopropylamine platinum(II) as a major metabolite of iproplatin in humans, doi
  69. (2002). In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer, doi
  70. (1990). In vitro biotransformations of tetrachloro(d,ltrans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma, doi
  71. (1999). In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin,
  72. (1996). In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells, doi
  73. (2003). Induced-fit recognition of DNA by organometallic complexes with dynamic stereogenic centers, doi
  74. (2002). Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A, doi
  75. (2005). Influence of dT20 and [d(AT)10]2 on cisplatin hydrolysis studied by two-dimensional [1H,15N] doi
  76. (1965). Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode, doi
  77. (2002). Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A, doi
  78. (1970). Inhibitory effects of antitumor platinum compounds on DNA, RNA, and protein syntheses in mammalian cells in vitro, doi
  79. (1984). Interaction of the antitumor agents cis,cis,trans-Pt(IV)(NH3)2Cl2(OH)2 and cis,cis,transPt(IV)[(CH3)2CHNH2]2Cl2(OH)2 and their reduction products with PM2 doi
  80. (2001). Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein, doi
  81. (1974). Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand crosslinking and cytotoxic properties of platinum(II) compounds, doi
  82. (1993). Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin, doi
  83. (1999). Kinetic aspects of interactions between DNA and platinum complexes, doi
  84. (2001). Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA, doi
  85. (2008). KP1019, a new redoxactive anticancer agent - preclinical development and results of a clinical phase I study in tumor patients, doi
  86. (2003). Leptomycin B enhances CDDPsensitivity via nuclear accumulation of p53 protein in HPV-positive cells, doi
  87. (2004). Long Range 1,4 and 1,6-Interstrand Cross-Links Formed by a Trinuclear Platinum Complex. Minor Groove Preassociation Affects Kinetics and Mechanism of Cross-Link Formation as Well as Adduct Structure, doi
  88. (1986). Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA,
  89. (2004). Mechanism of two-electron oxidation of deoxyguanosine 5'-monophosphate by a platinum(IV) complex, doi
  90. (2008). Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents, doi
  91. (2008). Metal-ligand exchange kinetics in platinum and ruthenium complexes. Significance for effectiveness as anticancer drugs, doi
  92. (1988). Modelling the interaction of cisplatin with DNA,
  93. (1987). Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II), doi
  94. (2003). Multi-nuclear platinum complexes as anti-cancer drugs, doi
  95. (2005). Multi-nuclear platinum drugs: A new paradigm in chemotherapy, doi
  96. (1993). New cisplatin analogs in development: a review, doi
  97. (2004). New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes, doi
  98. (1998). NMR Solution Structure of a DNA Dodecamer Duplex Containing a cis-Diammineplatinum(II) D(GpG) doi
  99. (2004). NMR Solution Structure of an Oxaliplatin 1,2-d(GG) Intrastrand Cross-link in a DNA Dodecamer Duplex, doi
  100. (1980). Oncological implication of the chemistry of ruthenium,
  101. (2007). Osmium(II) and ruthenium(II) arene maltolato complexes: rapid hydrolysis and nucleobase binding, doi
  102. (1996). Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell doi
  103. (1998). Oxaliplatin: a review of preclinical and clinical studies, doi
  104. (2005). Oxidation of Guanosine Derivatives by a Platinum(IV) Complex: Internal Electron Transfer through Cyclization, doi
  105. (1970). Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo,
  106. (2005). Pharmacokinetics and tissue distribution of platinum in rats following single and multiple oral doses of LA-12 [(OC-6-43)-Unusual DNA binding modes for metal anticancer complexes bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV)], doi
  107. (1998). Pharmacological control of lung metastases of solid tumors by a novel ruthenium complex,
  108. (1994). Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule,
  109. (2005). Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer, doi
  110. (2007). Photoactivatable platinum complexes, doi
  111. (2009). Photoaffinity isolation and identification of proteins in cancer cell extracts that bind to platinum-modified DNA, doi
  112. (2009). Photoinduced reactions of cis,trans,cis-[Pt(IV)(N3)2(OH)2(NH3)2) with 1-methylimidazole, doi
  113. (1996). Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light, Anti-Cancer Drug Des.
  114. (2001). Platinum binding to DNA: structural controls and consequences, doi
  115. (1999). Platinum complexes: hydrolysis and binding to N(7) and N(1) of purines, in: doi
  116. (1995). Platinum(II) complexes containing iminoethers: a trans platinum antitumor agent, doi
  117. (2002). Platinum(IV) antitumour compounds: their bioinorganic chemistry, doi
  118. (2004). Platinum(IV) Complex with Adamantylamine as Nonleaving Amine Group: Synthesis, Characterization, and in Vitro Antitumor Activity against a Panel of Cisplatin-Resistant Cancer Cell Lines, doi
  119. (2005). Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12, doi
  120. (1998). Rates of Platination of AG and GA Containing Double-Stranded Oligonucleotides: Insights into Why Cisplatin Binds to doi
  121. (1993). Reaction of mertrichloro(diethylenetriamine)platinum(IV) chloride, (mer-[Pt(dien)Cl3]Cl), with purine nucleosides and nucleotides results in formation of platinum(II) as well as platinum(IV) complexes, doi
  122. (1986). Reaction products from platinum(IV) amine compounds and 5'-GMP are mainly bis(5'-GMP)platinum(II) amine adducts, doi
  123. (1987). Reactions of platinum(IV) amine compounds with 9-methylhypoxanthine at high temperature result in both platinum(II) and platinum(IV) amine adducts, doi
  124. (2005). Reactions of Potent Antitumor Complex trans-[RuIIICl4(indazole)2]- with a DNA-Relevant Nucleobase and Thioethers: Insight into doi
  125. (2003). Recent developments in the field of tumor-inhibiting metal complexes, doi
  126. (2005). Recognition and processing of cisplatin- and oxaliplatin-DNA adducts, doi
  127. (2001). Recognition of cisplatin adducts by cellular proteins, doi
  128. (2005). Redox-Active Antineoplastic Ruthenium Complexes with Indazole: Correlation of in Vitro Potency and Reduction Potential, doi
  129. (1986). Reevaluation of interaction of cisdichloro(ethylenediamine)platinum(II) with DNA, doi
  130. (1999). Relationships between reduction properties and cancer cell growth inhibitory activities of cis-dichloro- and cis-diiodoPt(IV)-ethylenediamines, doi
  131. (2006). Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes, doi
  132. (2007). Ruthenium anticancer compounds: challenges and expectations, doi
  133. (2004). Ruthenium antimetastatic agents, doi
  134. (2006). Satraplatin: an orally available platinum analog for the treatment of cancer, Expert Rev. Anticancer Ther. doi
  135. (2000). Slowing of Cisplatin Aquation doi
  136. (2007). Solution Structures of a DNA Dodecamer Duplex with and without a doi
  137. (1999). Specificity of platinum-DNA adduct repair, doi
  138. (2006). Structural aspects of Pt-DNA adduct recognition by proteins, DNA Damage Recognition doi
  139. (1975). Structure and activity relations of platinum complexes with antitumor activity, doi
  140. (1999). Structure, recognition, and processing of cisplatinDNA adducts, doi
  141. (1999). Substitution and Reduction of Platinum(IV) Complexes by a Nucleotide, doi
  142. (2003). Synthesis, X-ray Diffraction Structures, Spectroscopic Properties, and in vitro Antitumor Activity of Isomeric (1H-1,2,4-Triazole)Ru(III) doi
  143. (1986). Tetravalent platinum complexes can exert their antitumor effect via direct reaction with DNA,
  144. (1982). The antitumor drug cisdichlorodiammineplatinum forms an intrastrand d(GpG) crosslink upon reaction with [d(ApGpGpCpCpT)]2, doi
  145. (2000). The chemistry of cisplatin in aqueous solution, doi
  146. (2005). The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells, Cancer Lett. doi
  147. (1989). The hydrolysis products of cisdichlorodiammineplatinum(II). 2. The kinetics of formation and anation of the cis-diamminedi(aqua)platinum(II) cation, doi
  148. (1999). The mechanism of action of cisplatin: from adducts to apoptosis, in: doi
  149. (1980). The nature of inactivating lesions produced by platinum(II) complexes in phage l DNA, doi
  150. (2003). Theoretical Study of Cisplatin Binding to Purine Bases: Why Does Cisplatin Prefer Guanine over Adenine?, doi
  151. (2006). Transplatin Is Cytotoxic When Photoactivated: doi
  152. (2004). Tuning of Redox Potentials for the Design of Ruthenium Anticancer Drugs - an Electrochemical Study of [trans-RuCl4L(DMSO)]- and [trans-RuCl4L2]- Complexes, doi
  153. (2007). Tuning the Hydrolytic Aqueous Chemistry of Osmium Arene Complexes with N,O-Chelating Ligands to Achieve Cancer Cell Cytotoxicity, doi
  154. (2008). Unprecedented carbon-carbon bond formation induced by photoactivation of a platinum(iv)-diazido complex, doi
  155. (2004). Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes, doi
  156. (1999). Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell?, doi
  157. X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis- doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.